| Code | CSB-RA006163MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BMS-986218, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4 signaling is implicated in autoimmune diseases, while its pathway is exploited by tumors to evade immune surveillance, making it a significant target in immuno-oncology and autoimmunity research.
BMS-986218 represents a next-generation anti-CTLA4 antibody developed to modulate immune responses with potentially improved selectivity compared to earlier CTLA4-targeting agents. This biosimilar provides researchers with a valuable tool for investigating CTLA4-mediated immune regulation, studying T-cell exhaustion mechanisms, exploring combination immunotherapy strategies, and evaluating immune checkpoint biology in various disease models. It supports mechanistic studies of T-cell activation, tumor microenvironment interactions, and therapeutic intervention development.
There are currently no reviews for this product.